Translate Bio

General Information
Business:

 

 

We are a leading messenger RNA, or mRNA, therapeutics company developing a new class of potentially transformative medicines to treat diseases caused by protein or gene dysfunction. Using our proprietary mRNA therapeutic platform, or MRT platform, we create mRNA that encodes functional proteins. We believe that the mRNA design, delivery and manufacturing capabilities of our MRT platform provide us with the most advanced platform for developing product candidates that deliver mRNA encoding functional proteins for therapeutic uses.

 

Industry: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES)
Employees: 61
Founded: 2016
Contact Information
Address 29 Hartwell Avenue, Lexington, MA 02421, US
Phone Number (617) 945-7361
Web Address http://www.translate.bio
View Prospectus: Translate Bio
Financial Information
Market Cap $560.6mil
Revenues $0 mil (last 12 months)
Net Income $-74.4 mil (last 12 months)
IPO Profile
Symbol TBIO
Exchange NASDAQ
Shares (millions): 7.7
Price range $12.00 - $14.00
Est. $ Volume $100.1 mil
Manager / Joint Managers Citigroup/ Leerink Partners/ Evercore ISI
CO-Managers -
Expected To Trade: 6/28/2018
Day: Thursday
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change